Treatment of latent tuberculosis infection in HIV infected persons
- 26 January 2004
- reference entry
- review article
- Published by Wiley
- No. 1,p. CD000171
- https://doi.org/10.1002/14651858.cd000171.pub2
Abstract
Individuals with HIV infection are at an increased risk of developing active tuberculosis. It is known that treatment of latent tuberculosis infection (LTBI), also referred to as preventive therapy or chemoprophylaxis, helps to prevent progression to active disease in human immunodeficiency virus (HIV) negative populations. However, the extent and magnitude of protection (if any) associated with preventive therapy in those infected with HIV should be quantified. To determine the effectiveness of tuberculosis preventive therapy in reducing the risk of active tuberculosis and death in persons infected with HIV. We searched the Cochrane Controlled Trials Register (CCTR), MEDLINE, EMBASE, AIDSLINE, AIDSTRIALS and AIDSDRUGS. We also scanned reference lists of articles and contacted authors and other researchers in the field. We included studies in which HIV positive individuals were randomly allocated to preventive therapy for TB and placebo, or to alternative TB preventive therapy regimens. Participants could be tuberculin skin test positive or negative, but without active tuberculosis. Two reviewers independently applied study selection criteria, assessed study quality and extracted data. Effects were assessed using relative risk for dichotomous data and weighted mean difference for continuous data. 11 trials were included with a total of 8,130 randomized participants. Preventive therapy (any anti-TB drug) versus placebo was associated with a lower incidence of active tuberculosis (RR 0.64, 95% CI 0.51 to 0.81). This benefit was more pronounced in individuals with a positive tuberculin skin test (RR 0.38, 95% CI 0.25 to 0.57) than in those who had a negative test (RR 0.83, 95% CI 0.58 to 1.18.). Limited data suggest that the initial protective effect against tuberculosis may decline over the short to medium term. Efficacy was similar for all regimens (regardless of drug type, frequency or duration of treatment). However, compared to INH monotherapy, short -course multi-drug regimens were much more likely to require discontinuation of treatment due to adverse effects. Overall, there was no evidence that preventive therapy versus placebo reduced all-cause mortality (RR 0.95, 95% CI 0.85 to 1.06), although a favourable trend was found in people with a positive tuberculin test (RR 0.80, 95% CI 0.63 to 1.02). Treatment of latent tuberculosis infection (LTBI) reduces the risk of active tuberculosis in HIV positive individuals with a positive tuberculin skin test. The choice of regimen will depend on factors such as cost, adverse effects, adherence and drug resistance. Future studies should assess these aspects. In addition, trials evaluating the long-term effects of anti-tuberculosis chemoprophylaxis and the influence of level of immunocompromise on effectiveness are needed.Keywords
This publication has 23 references indexed in Scilit:
- Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adultsAIDS, 2001
- Interactions among Drugs for HIV and Opportunistic InfectionsNew England Journal of Medicine, 2001
- Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adultsAIDS, 2001
- Twice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS, 1998
- A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1997
- A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for TuberculosisNew England Journal of Medicine, 1997
- Isoniazid preventive therapy for tuberculosis in HIV-1-infected adultsAIDS, 1997
- A prospective study of the risk of tuberculosis among HIV-infected patientsAIDS, 1993
- Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infectionThe Lancet, 1993
- A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1989